0.420
0.00 (1.16%)
| Previous Close | 0.415 |
| Open | 0.420 |
| Volume | 152,374 |
| Avg. Volume (3M) | 970,739 |
| Market Cap | 9,090,964 |
| Price / Book | 2.87 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2025 |
| Diluted EPS (TTM) | -0.160 |
| Total Debt/Equity (MRQ) | 50.08% |
| Current Ratio (MRQ) | 1.88 |
| Operating Cash Flow (TTM) | -4.76 M |
| Levered Free Cash Flow (TTM) | -2.00 M |
| Return on Assets (TTM) | -24.64% |
| Return on Equity (TTM) | -116.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Advanced Biomed Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| % Held by Insiders | 78.69% |
| % Held by Institutions | 0.05% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Sep 2025 | Announcement | Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |